| Net loss per share |
The components of basic and diluted loss per share were as
follows:
| |
|
Year ended March 31, |
|
| (In USD, except loss per share) |
|
2026 |
|
|
2025 |
|
| |
|
|
|
|
|
|
| Net loss available for common shareholders (A) |
|
$ |
(14,621,113 |
) |
|
$ |
(25,622,303 |
) |
| Weighted average outstanding shares of common stock (B) #^ |
|
|
11,451,192 |
|
|
|
490,140 |
|
| Dilutive effect of potentially dilutive outstanding securities |
|
|
- |
|
|
|
- |
|
| Common Stock and Common Stock Equivalents |
|
|
11,451,192 |
|
|
|
490,140 |
|
| Loss per share |
|
|
|
|
|
|
|
|
| Basic (A/B) |
|
$ |
(1.28 |
) |
|
$ |
(52.28 |
) |
| Diluted (A/C) |
|
$ |
(1.28 |
) |
|
$ |
(52.28 |
) |
| # | Prior
period numbers have been adjusted to reflect the First Reverse Stock Split and the Second Reverse Stock Split of the Common Stock at
a ratio of 1-for-100 and 1-for-20 respectively. (Refer Note 3A) |
| ^ | Including pre-funded/cashless exercise warrants. |
Share related amounts have been retroactively adjusted to reflect
the reverse stock-split for all periods presented.
Since the Company was in a loss position for the year ended
March 31, 2026 and March 31, 2025, basic loss per share was same as diluted net loss per share for the years presented. The following
potentially dilutive outstanding securities as of March 31, 2026 and March 31, 2025 were excluded from the computation of diluted loss
per share because their effect would have been anti-dilutive for the years presented, or issuance of such shares is contingent upon the
satisfaction of certain conditions which were not satisfied by the end of the year.
| | |
Year ended March 31, | |
| | |
2026 | | |
2025 | |
| Convertible preferred stock | |
| | |
| |
| Preferred stock warrants | |
| | |
| |
| Stock options* | |
| 16 | | |
| 16 | |
| Restricted Stock Units (Refer Note 26) | |
| 4,216,250 | | |
| 17,966 | |
| Public warrants | |
| 11,500,000 | | |
| 11,500,000 | |
| Private warrants | |
| 19,180 | | |
| 19,180 | |
| Warrants issued along with redeemable promissory note | |
| 5,297 | | |
| 5,297 | |
| Warrants issued in February 2026 private placement offering | |
| 939 | | |
| - | |
| Warrants issued in November 2024 and December 2024 offering (including Second and Third closing of December offering) | |
| 3,472,777 | | |
| 12,335,519 | |
| Total | |
| 19,214,459 | | |
| 23,877,978 | |
| * | In 2012, the Company adopted its 2012 Equity Incentive Plan,
under which the Company may grant options and restricted stock to eligible participants. The plan is equity settled. Options are generally
granted for a term of ten years. Options have a graded vesting period of up to four years and the expenses are recorded on a straight-line
basis over the requisite service period for each separately vesting portion of the awards. The Company cancelled certain outstanding
options at the time of Reverse Recapitalization. The remaining 16 fully vested options were assumed by the Company on the Reverse Recapitalization
date, exercisable at exercise price ranging from $120 to $300. |
|